Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes

Articles with lock require a subscription to GLG News | Request a free trial
September 26, 2007
Accomplia: Does it accomplish enough?
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Expert Contributor
Weight loss is good but the amount and time to reach goal is more important then just the weight loss potential itself
September 24, 2007
Is the Betterment of Diabetes just a Weight-loss Phenomenon?
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
A weight loss of at least 10% of original body weight has been found to reduce insulin resistance.  The amount of weight loss seen after gastric by-pass has led to a partial or compete reversal of diabetes with some patients going off therapy completely.  In some patients, there is a regain...
September 21, 2007
Exubera: To Little , Too Late
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Expert Contributor
Long term studies of Exubera do little to reassure the product's safety. This is especially true in the face of new insulin pens that are safe, effective and makes it very easy to administer insulin.
September 17, 2007
EVISTA - the First for Breast Cancer Prevention and Osteoporosis Treatment..BUT
Analysis of: FDA approves Lilly's Evista for breast cancer | www.marketwatch.com
Author: GLG Expert Contributor
Evista sales may improve due to the FDA approval for both prevention of invasive breast cancer and osteoporosis but the increase is likely to be very modest.  It has advantages over tamoxifen in that Evista does not cause endometrial hyperplasia or cancer of the uterus, however it still carries...
September 10, 2007
GLP-1 ANALOGUES AND DPP4 INHIBITORS
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Expert Contributor
The fewer the injections, the more market share if all else is the same. We will await to see how needle size will affect LAR acceptance. My estimate is that it will absolutely not. Patients never asked what the size of the needle was prior to initiation of BYETTA bid--they just heard "weight loss and...
September 10, 2007
Compliance with pharmacotherapy in the Type II / Metabolic Syndrome Patient
Analysis of: Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA | www.pipelinereview.com
Author: GLG Expert Contributor
OADs such as sulfonylureas and glitinides are being displaced today with the advent of sitagliptin for those who have coverage for this medication.
September 7, 2007
Liraglutide is a small step forward, but there will be bigger steps to come shortly.
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Expert Contributor
Liraglutide will steal some market share from the leader, exenatide, but if exenatide comes out in a once a week formulation and other similar products even less often, the market will shift again.
September 4, 2007
Avandia, data, and PR damage
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Expert Contributor
-reassuring clinical data -severe PR damage
September 3, 2007
Liraglutide, potenital, and barriers
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Expert Contributor
-Key therapeutic class -difficult competition
September 3, 2007
Mitiglinide—Thrice Your Out
Analysis of: Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA | www.pipelinereview.com
Author: GLG Expert Contributor
Mitiglinide may have a role in specific subtypes of diabetes patients, but it thrice a day dosing in a hurdle for all but the compulsive few.

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next41 to 50 of 93

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747